2025
Use of AMD3100 for Bone Marrow Derived Mesenchymal Stem Cells Mobilization in the Treatment of Murine Asherman’s Syndrome
Flores V, Delis P, Mamillapalli R, Taylor H. Use of AMD3100 for Bone Marrow Derived Mesenchymal Stem Cells Mobilization in the Treatment of Murine Asherman’s Syndrome. F&S Science 2025 PMID: 40818715, DOI: 10.1016/j.xfss.2025.08.003.Peer-Reviewed Original ResearchAsherman's syndromePreterm ruptureAS inductionMurine modelProgenitor cellsMesenchymal stem cell mobilizationMice treated with AMD3100Preterm rupture of membranesAMD3100-treated miceRupture of membranesOptimal timingStem cell mobilizationBone marrow transplantationTreatment groupsLevels of CXCL12Source of progenitor cellsRecurrent pregnancy lossEndometrial progenitor cellsBMD-MSCsLikelihood of pregnancyHysteroscopic adhesiolysisPlacental abruptionUterine repairSevere ASMarrow transplantationTwo-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials
Donnez J, Petraglia F, Taylor H, Becker C, Becker S, Herrera F, Paszkowski M, Bestel E, Hori S, Dolmans M. Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials. Human Reproduction Open 2025, 2025: hoaf025. PMID: 40575397, PMCID: PMC12202088, DOI: 10.1093/hropen/hoaf025.Peer-Reviewed Original ResearchDual-energy X-ray absorptiometryTotal hip bone mineral densityHip bone mineral densityBone mineral densityBaseline to monthAdd-back therapyLumbar spine bone mineral densitySpine bone mineral densityBone mineral density valuesAmerican Society of Reproductive MedicinePlacebo groupClinically relevant impactLumbar spineGedeon RichterOverall bone healthFemoral neckBaseline valuesTreatment groupsPrimary endpointSecondary endpointsL1-L4DEXA scanMineral densityFollow-up studyPre-treatment baseline values
2022
Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]
Al-Hendy A, Bradley L, Taylor H, Catherino W, Humberstone A, Garner E. Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]. Obstetrics And Gynecology 2022, 139: 31s-31s. DOI: 10.1097/01.aog.0000826748.26150.66.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsPlacebo-controlled phase 3 trialTreatment of UFsFibroid-related symptomsHealth-related qualifyOral GnRH antagonistHealth-related qualityEnd of treatmentLong-term impairmentSubstantial beneficial effectPlacebo groupGnRH antagonistLife QuestionnaireSexual functionWeek 64Mean changeFrequent causeTreatment terminationEstradiol suppressionTreatment groupsLinzagolixPooled populationBeneficial effectsTotal score
2019
Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback
Kling JM, Dowling NM, Bimonte-Nelson HA, Gleason CE, Kantarci K, Manson JE, Taylor HS, Brinton EA, Lobo RA, Cedars MI, Pal L, Neal-Perry G, Naftolin F, Harman SM, Miller VM. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. AJP Regulatory Integrative And Comparative Physiology 2019, 317: r912-r920. PMID: 31663769, PMCID: PMC6957372, DOI: 10.1152/ajpregu.00234.2019.Peer-Reviewed Original ResearchConceptsFollicle-stimulating hormoneKronos Early Estrogen Prevention StudyHormone levelsHormone therapyT-E2Menopausal womenTreatment groupsOral conjugated equine estrogenCommon hormone therapiesPituitary-ovarian hormonesPostmenopausal hormone therapyActive treatment groupConjugated equine estrogensMo of treatmentDouble-blinded treatmentPlacebo groupEquine estrogensMenopausal transitionPrevention StudyO-CEEHormonal modulationBaseline levelsCognitive declinePlaceboHormone formulationsEffects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial
Khoudary S, Zhao Q, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman SM, Cedars MI, Hopkins PN, Kearns AE, Miller VM, Taylor HS, Budoff MJ. Effects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial. Journal Of The American Heart Association 2019, 8: e012763. PMID: 31652073, PMCID: PMC6761637, DOI: 10.1161/jaha.119.012763.Peer-Reviewed Original ResearchConceptsOral conjugated equine estrogenConjugated equine estrogensCoronary artery calcification (CAC) progressionBaseline CAC scoreEpicardial adipose tissueCAC scoreEquine estrogensMenopausal womenCAC progressionCalcification progressionAdipose tissueEpicardial adipose tissue accumulationEarly menopausal womenPlacebo-controlled trialAdipose tissue accumulationHormone therapy formulationsProgression of CACKEEP participantsHormone therapySubclinical atherosclerosisCAC measuresEndogenous estrogensFat accumulationTreatment groupsFat depots
2018
Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis
Hufnagel D, Goetz L, Hu Z, Nyachieo A, D’Hooghe T, Fazleabas A, Duleba A, Krikun G, Taylor HS, Lockwood CJ. Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis. Reproductive Biology 2018, 18: 109-114. PMID: 29422377, DOI: 10.1016/j.repbio.2018.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAdnexal DiseasesAmino Acid SubstitutionAnimalsEndometriosisFactor VIIFemaleGenetic TherapyGenetic VectorsHumansImmunoconjugatesImmunoglobulin Fc FragmentsImmunoglobulin GMolecular Targeted TherapyMutationNeovascularization, PathologicPapio anubisPelvisPeptide FragmentsRandom AllocationRecombinant Fusion ProteinsThromboplastinConceptsNon-human primatesNovel treatmentsTissue factorNon-human primate modelRegression of endometriosisEctopic endometrial tissueReproductive-aged womenEctopic endometrial lesionsWeekly intraperitoneal injectionsFactor VII/VIIaLesion vasculatureChronic painEndometrial lesionsEndometrial tissueEndometriosis lesionsLaparoscopic confirmationSurgical inductionIntraperitoneal injectionPrimate modelCommon conditionMurine modelEndometriosisTreatment groupsControl groupTreatment results
2017
Effect of simvastatin on baboon endometriosis†
Taylor HS, Alderman M, D'Hooghe TM, Fazleabas AT, Duleba AJ. Effect of simvastatin on baboon endometriosis†. Biology Of Reproduction 2017, 97: 32-38. PMID: 28637327, PMCID: PMC6248548, DOI: 10.1093/biolre/iox058.Peer-Reviewed Original ResearchConceptsEffect of simvastatinEndometriotic lesionsRed lesionsMarkers of inflammationEndometrial stromal cellsDevelopment of endometriosisEstrogen receptor betaImmune system activationEstrogen receptor alphaMarkers of proliferationSteroid hormone responsesCell nuclear antigenEndometrial lesionsEndometrial tissueEutopic endometriumReproductive agePrimate modelWhite lesionsCommon disorderEstrogen receptorBaboon modelMurine modelTreatment groupsSystem activationReceptor alpha
2016
Aromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis
Cho S, Mutlu L, Zhou Y, Taylor HS. Aromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis. Fertility And Sterility 2016, 106: 673-680. PMID: 27320036, PMCID: PMC5831184, DOI: 10.1016/j.fertnstert.2016.05.020.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsLet-7f mimicIshikawa cellsL treatment groupEndometrial cellsAromatase expressionTreatment groupsEndometrial stromal cellsAromatase inhibitor treatmentPathogenesis of endometriosisLet-7f expressionSignificant differencesDose-dependent mannerLetrozole treatmentModulation of microRNAsAromatase inhibitorsLaparoscopic surgeryMAIN OUTCOMEAI treatmentEndometriosisLetrozole concentrationsTherapeutic levelsInhibitor treatmentControl groupTherapeutic potential
2015
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study
Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ, Lobo RA, Taylor HS, Manson JE, Black DM, Naftolin F, Harman SM, de Andrade M. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics 2015, 48: 33-41. PMID: 26508701, PMCID: PMC4757027, DOI: 10.1152/physiolgenomics.00029.2015.Peer-Reviewed Original ResearchConceptsCarotid artery intima-medial thicknessKronos Early Estrogen Prevention StudyMenopausal hormone treatmentCoronary arterial calcificationInnate immunity pathwaysIntima-medial thicknessImmunity pathwaysArterial calcificationPrevention StudySingle nucleotide polymorphismsOral conjugated equine estrogenConjugated equine estrogensTreatment effectsAgatston unitsPlacebo pillsEquine estrogensTreatment outcomesHormonal statusTreatment groupsParticipants 4Hormone treatmentCardiovascular phenotypesPharmacogenomic effectsYr changesEstrogen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply